ArticleVaccines2026

Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study.

Alpana Waghmare et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.